AviadoBio

We’re thrilled to announce our new exclusive option-license agreement with UgeneX Therapeutics for UGX-202, a novel, investigational #GeneTherapy designed to potentially restore vision in people living with #RetinitisPigmentosa and other retinal diseases. tinyurl.com/33v2jpyj

We’re leaving ASGCT 2026 energized after connecting with leaders across the gene therapy community and presenting new preclinical data for our AVB-406 program in Alzheimer’s disease and other tauopathies. Read more about the data here: aviadobio.com/aviadobio-pres… @ASGCTherapy

Today, we announced positive preclinical data for our AVB-406 program at ASGCT 2026, supporting our plans to advance AVB-406 into clinical trials for Alzheimer's disease by the end of the year. Read more about the data here: aviadobio.com/aviadobio-pres… @ASGCTherapy #GeneTherapy

This week marks the start of #ASGCT2026. We look forward to connecting with the broader CGT community and presenting data on AVB-406 and our proprietary vMiX™ RNAi platform. If you’re attending ASGCT, let’s connect. #GeneTherapy @ASGCTherapy

We’re looking forward to sharing more about our proprietary vMiX™ RNAi gene silencing platform at #ASGCT2026. vMiX is designed for potent and tolerable gene silencing, enabling new approaches to precision gene therapy for neurodegenerative diseases. ​​Learn more ↓

Thank you to everyone who made the AFTD Education Conference 2026 so meaningful. We’re grateful for the opportunity to connect with patients, families, and advocates, and to hear firsthand the experiences that continue to shape and inspire our work at AviadoBio. @AFTDHope

Our CEO, Lisa Deschamps, is on the ground at Bio€quity Europe 2026, where she’ll be joining “The Race for Speed” panel discussing how European biotechs can accelerate to compete and lead in today’s global landscape. Don’t miss this discussion tonight at 6:30 PM CET. @BioCentury

📍We’re onsite at the AFTD Education Conference 2026. There’s nothing more powerful than coming together with the FTD community united by a shared commitment to progress. If you’re here, come say hello! #AFTD2026 @AFTDHope #FrontotemporalDementia

Today, we announced our agreement with Apertura to license TfR1 CapX™, a novel capsid we'll leverage to advance investigational one-time genetic medicines for neurodegenerative diseases, including AVB-406 in Alzheimer’s & related tauopathies. Learn more: aviadobio.com/aviadobio-anno…

Our Chief Technology Officer, Alex Bloom, is speaking on Tuesday at the Cell & Gene Therapy Summit at ChinaBio about navigating investigator-initiated trials in China for gene therapy development. Interested in attending? Learn more: #cell-gene-therapy-summit-pudong-ballroom-4_navigating-investigator-initiated-trials-in-china-a-practical-roadmap-for-gene-therapy-development" target="_blank" rel="nofollow noopener">informaconnect.com/cell-gene-ther… #GeneTherapy

Next week, our CEO Lisa Deschamps will join the “Ethics and ATMPs” panel at Meeting on the Med to explore the evolving ATMP landscape with other industry leaders. Learn more about the panel: meetingonthemed.com/agenda/ #MeetingOnTheMed #Biotech

We’re heading to ASGCT 2026 next month! We look forward to engaging in meaningful discussions, sharing insights, and continuing to push the boundaries of what’s possible in gene therapy. Also attending? Contact us. @ASGCTherapy #ASGCT26 #GeneTherapy #Biotech

We’re looking forward to attending the AFTD Education Conference 2026 this month as we connect with patients, families, advocates, and the broader FTD community — learning and sharing the progress we’re making together. If you’re attending, we’d love to connect. @AFTDHope

Did you know? RP is a leading cause of visual disability & blindness, yet there are no treatments for late-stage photoreceptor loss. We're working to change that by advancing AVB-307, an intravitreally-delivered AAV #optogenetic investigational therapy. aviadobio.com/retinitis-pigm…

Breakthrough science starts with the right people. We believe building a team fueled by purpose and relentlessness drives real progress, especially when tackling big challenges. Learn more from CEO Lisa Deschamps on what drives #TeamAviadoBio. #BiotechTeams

Congratulations to Senior Research Associate, Debs Ojutalayo, on being named Rising Star at the Black Professionals in Life Sciences (#BPLS) Inspire Awards 2026. We’re proud to see her recognized for her leadership and commitment to innovation and inclusion in UK life sciences.

We’re pleased to announce AviadoBio initiated enrollment for the fourth cohort of our Phase 1/2 ASPIRE-FTD trial evaluating AVB-101 in FTD-GRN and shared encouraging early biomarker and safety data. Read more here: aviadobio.com/aviadobio-adva…

#GeneTherapy for neurological diseases is advancing rapidly, but delivery remains one of the field’s greatest challenges. Through innovative delivery technology and a deep commitment to patients, we’re working to redefine what’s possible. Learn more: aviadobio.com/delivery/

We were honored to attend the #AFTD Hope Rising Benefit and stand alongside patients, advocates, caregivers, researchers, and leaders united in their commitment to the #FrontotemporalDementia (#FTD) community. Thank you, @AFTDHope, for a wonderful and meaningful evening.

As #BrainAwarenessWeek comes to a close, we want to thank the advocates who drive progress every day for a better future. Your voices raise awareness, advance brain research, and keep the needs of patients and families at the center of the conversation.

It’s #BrainAwarenessWeek. Billions of neurons support behavior, language, memory, and emotion. When these networks are damaged, as in neurodegenerative diseases like FTD, the effects are profound. Advancing #neuroscience research is key to better diagnosis and treatment.